Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company is headquartered in Thousand Oaks, California and currently employs 28,000 full-time employees. The company discovers, develops, manufactures and delivers medicines for the toughest diseases. The company focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. The company operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. The company markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. The company markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. The company markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Follow-Up Questions
What is Amgen Inc (AMGN)'s P/E Ratio?
The P/E ratio of Amgen Inc is 38.4672
Who is the CEO of Amgen Inc?
Mr. Robert Bradway is the Chairman of the Board of Amgen Inc, joining the firm since 2007.
What is the price performance of AMGN stock?
The current price of AMGN is $306.98, it has increased 3.46% in the last trading day.
What are the primary business themes or industries for Amgen Inc?
Amgen Inc belongs to Biotechnology industry and the sector is Health Care
What is Amgen Inc market cap?
Amgen Inc's current market cap is $165.2B
Is Amgen Inc a buy, sell, or hold?
According to wall street analysts, 31 analysts have made analyst ratings for Amgen Inc, including 7 strong buy, 14 buy, 16 hold, 2 sell, and 7 strong sell
